BRCA1 and cancer: While the combination of PARPi with immunotherapy holds potential for BRCA1/2‐mutant cancers, limited benefits have been reported in recent studies,[15] highlighting the need for alternative strategies to potentiate antitumor immunity and immunotherapy response.